Our finding leverages the fine effort of testing novel FGF19 engineered variants that could display anti-fibrotic and anti-inflammatory effects but also antitumoral actions, thus opening bona fide a novel pharmacological strategy for example in PFIC patients who are susceptible to HCC formation even in young age. The gene discussed is FGF19; the disease is hepatocellular carcinoma.